KRAS and non-small cell lung carcinoma: Binimetinib has been tested in the first-line setting in the phase IB SAKK 19/16 study, in combination with platinum-based chemotherapy, in patient with KRAS mutant NSCLC; the addition of binimetinib has not shown early signs of clinical activity (90).